IMPEL NEUROPHARMA INC (IMPL): Price and Financial Metrics


IMPEL NEUROPHARMA INC (IMPL): $6.95

0.33 (+4.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMPL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMPL Stock Price Chart Interactive Chart >

Price chart for IMPL

IMPL Price/Volume Stats

Current price $6.95 52-week high $34.75
Prev. close $6.62 52-week low $5.72
Day low $6.45 Volume 49,700
Day high $7.03 Avg. volume 104,288
50-day MA $6.78 Dividend yield N/A
200-day MA $9.49 Market Cap 161.07M

IMPEL NEUROPHARMA INC (IMPL) Company Bio


Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.


IMPL Latest News Stream


Event/Time News Detail
Loading, please wait...

IMPL Latest Social Stream


Loading social stream, please wait...

View Full IMPL Social Stream

Latest IMPL News From Around the Web

Below are the latest news stories about Impel Neuropharma Inc that investors may wish to consider to help them evaluate IMPL as an investment opportunity.

Epiq Partners, Llc Buys Macquarie Infrastructure Holdings LLC, AquaBounty Technologies Inc, ...

Investment company Epiq Partners, Llc (Current Portfolio) buys Macquarie Infrastructure Holdings LLC, AquaBounty Technologies Inc, Pfizer Inc, WisdomTree U.S.

Yahoo | January 25, 2022

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

Trudhesa ™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company''s Guidance Range Achieved Broad and Favorable Trudhesa ™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022 SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL ), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today provided updates on Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) launch progress ...

Benzinga | January 18, 2022

Impel NeuroPharma migraine spray Q4 2021 prescriptions exceed company expectations

With an October 2021 launch, Impel NeuroPharma saw 4.2K prescriptions written for its Trudhesa (dihydroergotamine mesylate) nasal spray for acute migraine headaches in Q4.

Seeking Alpha | January 18, 2022

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022 SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage

Yahoo | January 18, 2022

Towercrest Capital Management Buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, ...

Newtown, PA, based Investment company Towercrest Capital Management (Current Portfolio) buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, Invesco S&P 500 Equal Weight ETF, Impel NeuroPharma Inc, Kala Pharmaceuticals Inc, sells Vanguard FTSE Emerging Markets ETF, International Business Machines Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Towercrest Capital Management.

Yahoo | December 10, 2021

Read More 'IMPL' Stories Here

IMPL Price Returns

1-mo 12.10%
3-mo 7.42%
6-mo -25.43%
1-year -37.78%
3-year N/A
5-year N/A
YTD -19.47%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6412 seconds.